KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach [Yahoo! Finance]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Yahoo! Finance
has reached something over 20% of patients, with about 1,700 start forms and ~724 prescribing physicians amid early U.S., German and Japanese launches. Coverage is currently driven largely by medical-exception pathways (initially nearly 100%), with major PBMs beginning formulary discussions after roughly six months; KalVista uses a Quickstart hub to send initial cartons while commercial approvals and prior authorizations are pursued to speed patient starts. KalVista plans a Q3 NDA filing for an orally dissolving tablet for ages 2–11 (targeting approval mid-next year) and a short-term prophylaxis study, and finished the fiscal year with about $300 million in cash, saying it is " funded to profitability " and expects cash-flow breakeven within the first few years of launch. Interested in KalVista Pharmaceuticals, Inc.? Here are five stocks we like better. KalVista Pharmaceuticals (NASDAQ:KALV) CEO Ben Palleiko told investors at Needham & Company's 25th Annual Healthcare Conferen
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals (KALV) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KALV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- KalVista Pharmaceuticals (KALV) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KALV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> froMarketBeat
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial [Yahoo! Finance]Yahoo! Finance
KALV
Earnings
- 3/25/26 - Miss
KALV
Analyst Actions
- 3/26/26 - Stifel
KALV
Sec Filings
- 3/27/26 - Form 4
- 3/25/26 - Form 10-KT
- 3/25/26 - Form 8-K
- KALV's page on the SEC website